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Recent results show that the classic PDE5 inhibitor,
Viagra
® (sildenafil), can ameliorate much of the cardiac
pathology resulting from several different forms of car-
diac damage. These results have elicited great interest in
the use of this drug as a therapeutic agent, particularly
for treatment of diastolic cardiac dysfunction. In fact sev-
eral clinical trials are now enrolling and one published
trial shows promising results. Unfortunately, it is not
clear how this drug works at a molecular level to improve
cardiac function and not even clear what the initial mole-
cular target(s) are for Viagra
® in any of these studies.
Recent data from our group and others strongly suggest
that sildenafil, a “classical” PDE5 inhibitor, ameliorates
much of the diastolic dysfunction seen in older mdx
mice, animals having a disruption in the dystrophin gene.
However, our preliminary data suggests that tadalafil
does not cause this effect. Moreover, the usual accepted
target for sildenafil, PDE5, is not even expressed in adult
mouse cardiomyocyes; but an alternate or additional tar-
get, PDE1C is highly expressed in this cell type. Since
PDE1C, also can be substantially inhibited by sildenafil
(but not by tadalafil) we feel that the most likely molecu-
lar target for Viagra
® is a direct effect on PDE1C in the
cardiomyocyte itself. There also may be additional effects
on PDE5, but probably in another cell type. These topics
will be discussed in this talk.
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